Chemistry:Lexipafant
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H30N4O4S |
| Molar mass | 458.58 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lexipafant (BB-882, Zacutex) is a drug which acts as a potent and selective inhibitor of the phospholipid mediator platelet-activating factor (PAF). It was developed in the 1990s by British Biotech with several potential applications, including HIV-associated neurocognitive disorder and acute pancreatitis. Initial results were encouraging and it progressed as far as Phase III clinical trials, but final analysis of trial results showed that it failed to improve survival rates in pancreatitis despite some symptomatic improvement, and it was ultimately discontinued from development as a medicine, though it continues to be used as a model PAF inhibitor for pharmacology research.[1][2][3][4]
References
- ↑ "Platelet-activating factor". Scandinavian Journal of Gastroenterology. Supplement 219: 28–31. 1996. doi:10.3109/00365529609104996. PMID 8865468.
- ↑ "The Use of Lexipafant in the Treatment of Acute Pancreatitis". Platelet-Activating Factor and Related Lipid Mediators 2. Advances in Experimental Medicine and Biology. 416. 1996. pp. 365–370. doi:10.1007/978-1-4899-0179-8_59. ISBN 978-1-4899-0181-1.
- ↑ "Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis". Gut 48 (1): 62–69. January 2001. doi:10.1136/gut.48.1.62. PMID 11115824.
- ↑ "Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials". The European Journal of Surgery = Acta Chirurgica 168 (4): 215–219. 2002. doi:10.1080/11024150260102816. PMID 12440758.
 |  |
